Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29


ADAR1-mediated regulation of melanoma invasion.

Nemlich Y, Baruch EN, Besser MJ, Shoshan E, Bar-Eli M, Anafi L, Barshack I, Schachter J, Ortenberg R, Markel G.

Nat Commun. 2018 May 31;9(1):2154. doi: 10.1038/s41467-018-04600-2.


Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.

Kfir-Elirachman K, Ortenberg R, Vizel B, Besser MJ, Barshack I, Schachter J, Nemlich Y, Markel G.

Neoplasia. 2018 Apr;20(4):401-409. doi: 10.1016/j.neo.2018.01.012. Epub 2018 Mar 17.


CEACAM1-Mediated Inhibition of Virus Production.

Vitenshtein A, Weisblum Y, Hauka S, Halenius A, Oiknine-Djian E, Tsukerman P, Bauman Y, Bar-On Y, Stern-Ginossar N, Enk J, Ortenberg R, Tai J, Markel G, Blumberg RS, Hengel H, Jonjic S, Wolf DG, Adler H, Kammerer R, Mandelboim O.

Cell Rep. 2016 Jun 14;15(11):2331-9. doi: 10.1016/j.celrep.2016.05.036. Epub 2016 Jun 2.


SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.

Ashkenazi S, Ortenberg R, Besser M, Schachter J, Markel G.

Oncotarget. 2016 May 24;7(21):30166-77. doi: 10.18632/oncotarget.7379.


Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy.

Ortenberg R, Sapoznik S, Zippel D, Shapira-Frommer R, Itzhaki O, Kubi A, Zikich D, Besser MJ, Schachter J, Markel G.

J Immunol Res. 2015;2015:902137. doi: 10.1155/2015/902137. Epub 2015 Nov 25.


Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kaynan N, Coppenhagen-Glazer S, Shussman N, Almogy G, Cuapio A, Hofer E, Mevorach D, Tabib A, Ortenberg R, Markel G, Miklić K, Jonjic S, Brennan CA, Garrett WS, Bachrach G, Mandelboim O.

Immunity. 2015 Feb 17;42(2):344-355. doi: 10.1016/j.immuni.2015.01.010. Epub 2015 Feb 10.


A longitudinal study of CEACAM1 expression in melanoma disease progression.

Zippel D, Barlev H, Ortenberg R, Barshack I, Schachter J, Markel G.

Oncol Rep. 2015 Mar;33(3):1314-8. doi: 10.3892/or.2014.3703. Epub 2014 Dec 30.


CEACAM1 promotes melanoma cell growth through Sox-2.

Ortenberg R, Galore-Haskel G, Greenberg I, Zamlin B, Sapoznik S, Greenberg E, Barshack I, Avivi C, Feiler Y, Zan-Bar I, Besser MJ, Azizi E, Eitan F, Schachter J, Markel G.

Neoplasia. 2014 May;16(5):451-60. doi: 10.1016/j.neo.2014.05.003. Epub 2014 Jun 13.


MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.

Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G.

J Clin Invest. 2013 Jun;123(6):2703-18.


Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.

Besser MJ, Shoham T, Harari-Steinberg O, Zabari N, Ortenberg R, Yakirevitch A, Nagler A, Loewenthal R, Schachter J, Markel G.

PLoS One. 2013;8(3):e57922. doi: 10.1371/journal.pone.0057922. Epub 2013 Mar 4.


Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma.

Itzhaki O, Greenberg E, Shalmon B, Kubi A, Treves AJ, Shapira-Frommer R, Avivi C, Ortenberg R, Ben-Ami E, Schachter J, Besser MJ, Markel G.

PLoS One. 2013;8(2):e57160. doi: 10.1371/journal.pone.0057160. Epub 2013 Feb 25.


Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.

Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Schachter J, Markel G.

Clin Dev Immunol. 2012;2012:818214. doi: 10.1155/2012/818214. Epub 2012 Apr 23. Review.


Persister-promoting bacterial toxin TisB produces anion-selective pores in planar lipid bilayers.

Gurnev PA, Ortenberg R, Dörr T, Lewis K, Bezrukov SM.

FEBS Lett. 2012 Jul 30;586(16):2529-34. doi: 10.1016/j.febslet.2012.06.021. Epub 2012 Jun 21.


Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions.

Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G.

Mol Cancer Ther. 2012 Jun;11(6):1300-10. doi: 10.1158/1535-7163.MCT-11-0526. Epub 2012 Mar 30.


CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy.

Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovski S, Levy D, Avivi C, Barshack I, Cohen CJ, Besser MJ, Schachter J, Markel G.

Cancer Immunol Immunother. 2012 Oct;61(10):1833-47. Epub 2012 Mar 24.


CEACAM1 in malignant melanoma: a diagnostic and therapeutic target.

Sapoznik S, Ortenberg R, Schachter J, Markel G.

Curr Top Med Chem. 2012;12(1):3-10. Review.


Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.

Khatib N, Pe'er J, Ortenberg R, Schachter J, Frenkel S, Markel G, Amer R.

Invest Ophthalmol Vis Sci. 2011 Dec 9;52(13):9368-72. doi: 10.1167/iovs.10-6006.


Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

Bland ND, Wang C, Tallman C, Gustafson AE, Wang Z, Ashton TD, Ochiana SO, McAllister G, Cotter K, Fang AP, Gechijian L, Garceau N, Gangurde R, Ortenberg R, Ondrechen MJ, Campbell RK, Pollastri MP.

J Med Chem. 2011 Dec 8;54(23):8188-94. doi: 10.1021/jm201148s. Epub 2011 Nov 8.


Regulation of cancer aggressive features in melanoma cells by microRNAs.

Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N, Markel G.

PLoS One. 2011 Apr 25;6(4):e18936. doi: 10.1371/journal.pone.0018936.


Systemic dysregulation of CEACAM1 in melanoma patients.

Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ, Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A, Schachter J.

Cancer Immunol Immunother. 2010 Feb;59(2):215-30. doi: 10.1007/s00262-009-0740-5.


Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.

Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, Treves AJ, Loewenthal R, Orenstein A, Nagler A, Schachter J.

PLoS One. 2009;4(5):e5597. doi: 10.1371/journal.pone.0005597. Epub 2009 May 19.


Short peptide induces an "uncultivable" microorganism to grow in vitro.

Nichols D, Lewis K, Orjala J, Mo S, Ortenberg R, O'Connor P, Zhao C, Vouros P, Kaeberlein T, Epstein SS.

Appl Environ Microbiol. 2008 Aug;74(15):4889-97. doi: 10.1128/AEM.00393-08. Epub 2008 May 30.


An alternative pathway for reduced folate biosynthesis in bacteria and halophilic archaea.

Levin I, Giladi M, Altman-Price N, Ortenberg R, Mevarech M.

Mol Microbiol. 2004 Dec;54(5):1307-18.


Interactions of glutaredoxins, ribonucleotide reductase, and components of the DNA replication system of Escherichia coli.

Ortenberg R, Gon S, Porat A, Beckwith J.

Proc Natl Acad Sci U S A. 2004 May 11;101(19):7439-44. Epub 2004 Apr 27.


Functions of thiol-disulfide oxidoreductases in E. coli: redox myths, realities, and practicalities.

Ortenberg R, Beckwith J.

Antioxid Redox Signal. 2003 Aug;5(4):403-11. Review.


Genetic evidence for a novel thymidylate synthase in the halophilic archaeon Halobacterium salinarum and in Campylobacter jejuni.

Giladi M, Bitan-Banin G, Mevarech M, Ortenberg R.

FEMS Microbiol Lett. 2002 Oct 29;216(1):105-9.


The extremely halophilic archaeon Haloferax volcanii has two very different dihydrofolate reductases.

Ortenberg R, Rozenblatt-Rosen O, Mevarech M.

Mol Microbiol. 2000 Mar;35(6):1493-505.

Supplemental Content

Loading ...
Support Center